top of page
cancer du cavum : CTI (TPF) + RTCT vs RTCT
histological WHO type 2 or 3, stage T2b, T3, T4 and/or N1-N3, M0, PS 0-1
![Essai Gortec NPC 2006-2 1.png](https://static.wixstatic.com/media/efdccd_c5a1702085204a0b90fcc7d9464c362b~mv2.png/v1/fill/w_450,h_275,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Essai%20Gortec%20NPC%202006-2%201.png)
![Essai Gortec NPC 2006-2 2.png](https://static.wixstatic.com/media/efdccd_f3d5ee10a67a4763b969b014ec703901~mv2.png/v1/fill/w_475,h_275,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Essai%20Gortec%20NPC%202006-2%202.png)
A Randomized Trial of Induction docetaxel-cisplatin-5FU Followed by Concomitant cisplatin-RT Versus Concomitant cisplatin-RT in Nasopharyngeal Carcinoma (GORTEC 2006-02)
​Ann Oncol​. 2018 Mar 1;29(3):731-736. doi: 10.1093/annonc/mdx770.
M Frikha, A Auperin, Y Tao, F Elloumi, N Toumi, P Blanchard, P Lang, S Sun, S Racadot, J Thariat, M Alfonsi, C Tuchais, A Cornely, A Moussa, J Guigay, J Daoud, J Bourhis, GORTEC
bottom of page